drugset / Trial / NCT06642792
A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a phase I/II study. All subjects are patients diagnosed with relapse or refractory (R/R) classic Hodgkin lymphoma (cHL) and has progressed on treatment with PD-1/L1 inhibitor therapy. The purpose of this study is to evaluate the safety and efficacy of AK129 (bispecific antibody targeting LAG-3 and PD-1) monotherapy or in combination with AK117 (anti-CD47 monoclonal antibody) in R/R cHL with PD-1/L1 inhibitor treatment failure.
Timeline
- Start
- 2025-01-17
- Primary completion
- 2027-11
- Completion
- 2028-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AK117 | Monoclonal antibody | 30 mg/kg | Intravenous |
| Subject | AK129 | Unknown | — | Intravenous |